Slide 1: Exchange filing cover letter for Q2 FY24 results presentation
October 31, 2023 The National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 (SYMBOL: THYROCARE) (SCRIP CODE 539871) Dear Sirs/Madam, Sub: Presentation- unaudited financial results f
Slide 2: Thyrocare Earnings Presentation Q2 FY24
3 Thyrocare Tests you can trust Thyrocare Earnings Presentation Q2 FY24
Slide 3: Safe harbour statement
Safe harbour statement Statements in this presentation describing the Company’s performance may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results may differ materially from those directly or indirectly expressed, inferred or implied.Impo
Slide 4: Agenda
Agenda he What Is Keeping Us Busy 02 Performance Highlights 03 Financial Performance 04 Going Forward Strategy 02
Slide 5: Key Business Highlights
Key Business Highlights Franchise > Awareness on Cardiac Bio Markers, Troponin | and Aarogyam 24/7 through KOLs and celebrities > Impetus on developing new brands, Jaanch (Investigative) — Revenue of Jaanch is now at ~1Cr permonth Public & Private Partnerships Awarded TB tenders under National Tuber
Slide 6: Agenda: Performance Highlights
Agenda 01 What Is Keeping Us Busy yee Performance Highlights 03 Financial Performance 04 Going Forward Strategy 04
Slide 7: Quarter health-check
Quarter health-check YoY TTL Consolidated Revenue* — YoY TTL Standalone YoY NHL Standalone Revenue Revenue NS — YoY Normalized ° T Normalized EBIDTA’ +8% EBITDA’ % — — *Note: Normalized EBIDTA is at consolidated level and is before non-cash charge of parent group API ESOPs and provisions for doubtfu
Slide 8: 10% Y-o-Y growth in overall business; 8% Y-o-Y growth in Normalized EBITDA
10% Y-0-Y growth in overall business; 8% Y-o-Y growth in Normalized EBITDA Consolidated Revenue (INR Cr) Normalized EBITDA (INR Cr) pete cena 10% «== een pecs cece: $B% cence ey ’ : ’ 148.0 42.5 135.0 135.9 134.9 39.6 406 iz 128.0 34.2 N N (oe) Re} oP) Te) N xt oO pe} is) nN oe) ve) N - N N 2) A oO
Slide 9: Franchise revenue grew by 20% Y-o-Y; Partnerships grew by 22%
Franchise revenue grew by 20% Y-o-Y; Partnerships (excluding API & B2G) grew by 22% Y-o0-Y Pathology Revenue (Rs Cr) YoY Growth Pathology Workload (Lakhs) 42.1 , 420% 39.6 86.3 39.0 . 38.5 36.0 Dip on account of API & B2G 174 17.3 4% 16.1 146 422% 13.0, + —_ 72 +19% Pca eanagnt ana ntnnnn een * 1.2
Slide 10: Agenda: Financial Performance
Agenda 01 What Is Keeping Us Busy 02 Performance Highlights (eke Financial Performance 04 Going Forward Strategy 08
Slide 11: Standalone Thyrocare quarterly financials
Quarter Growth % INR crore Q2 FY24 Q1 FY24 Q2 FY23 Seq. YOY Pathology revenue grew by 9% YoY, Revenue from operations 136.29 123.61 125.23 10% 9% while the Franchise business grew by Cost of materials consumed/ sold (41.25) (35.87) (39.46) 15% 5% 20%; Partnerships grew by 22% Gross margin 95.04 87.7
Slide 12: NHL standalone quarterly financials
Quarter Growth % INR crore Q2 FY24 Q1 FY24 Q2 FY23 Seq. YOY NHL Revenue grew 10% YoY on Revenue from operations 10.73 11.02 9.74 -3% 10% account of increased scan volume and Cost of materials consumed/ sold (2.30) (2.20) (1.67) 4% 38% FDG sales Gross margin 8.43 8.81 8.07 -4% 5% Employee benefit exp
Slide 13: Consolidated quarterly financials
Quarter Growth % INR crore Q2 FY24 Q1 FY24 Q2 FY23 Seq. YOY Revenue from operations Revenue from operations 148.00 134.89 134.97 10% 10% include Pulse Hitech Cost of materials consumed/ sold (43.63) (38.07) (41.12) 15% 6% Gross margin 104.37 96.82 93.85 8% 11% Employee benefit expenses (23.41) (21.9
Slide 14: Agenda: Going Forward Strategy
Agenda 01 What Is Keeping Us Busy 02 Performance Highlights 03 Financial Performance e~Going Forward Strategy
Slide 15: Vision & Mission
Vision & Mission J SD WO Vision ey Mission To be the best provider of diagnostic solutions to all stakeholders in healthcare - be it a single doctor, polyclinics, a health check up patient, a diagnostic lab, a nursing home, a large hospital, medical and health tech platforms or the Government To ens
Slide 16: Our strategy remains to be a B2B service provider
Our strategy remains to be a B2B service provider with an affordable value driven model based on scale efficiencies 4G Thyrocare Tests you can trust Franchise Partnership +B2G > Mom & Pop collection centers > Online diagnostics aggregators > Local labs > Healthcare platforms > Nursing homes & hospit
Slide 17: Going forward - Key pillars of growth
Going forward - Key pillars of growth . Public & Private International Franchise Partnerships Expansion > Going deeper into India with > Focus on TB and Infectious > Exploring to take our B2B focused test menu Disease along with large model to emerging markets to , a screening programs run by delive
Slide 18: Thank You
i, Thyrocare Tests you can trust For Any queries, please reach out to investor_relations@thyrocare.com Thank You Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publi